Wegovy tablets (oral semaglutide) vs Foundayo: how they compare
Wegovy tablets (oral semaglutide) and Foundayo (orforglipron) compared side by side: how they work, dosing, side effects and UK status.
Key differences
- Wegovy tablets (oral semaglutide) is a GLP-1 receptor agonist, while Foundayo is a non-peptide (small-molecule) GLP-1 receptor agonist.
- Both are taken once a day.
Side-by-side
| Attribute | Wegovy tablets (oral semaglutide) | Foundayo |
|---|---|---|
| Active ingredient | semaglutide (oral) | orforglipron |
| Drug class | GLP-1 receptor agonist | Non-peptide (small-molecule) GLP-1 receptor agonist |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Form | Tablet | Tablet |
| How often | once a day | once a day |
| Device | None (tablet) | None (tablet) |
| Starting dose | 1.5mg | 0.8mg |
| Dose range | 1.5mg to 25mg | 0.8mg to 17.2mg |
| UK status | Licensed in the UK for weight management | Licensed in the UK for weight management |
| NICE guidance | Not yet verified | Not yet verified |
| Common side effects | Nausea, Diarrhoea, Constipation, Vomiting, Indigestion and reflux | Nausea, Diarrhoea, Constipation, Vomiting, Indigestion and reflux |
Frequently asked questions
Comparison guides
- Ozempic vs Wegovy: Same Molecule, Different Licence
- Tablets vs Injections: Oral and Injectable GLP-1s Compared
- Orlistat vs GLP-1 Medications: How They Compare
- Mounjaro vs Wegovy: An Evidence-Based Comparison
- Mounjaro vs Oral GLP-1 Tablets
- Wegovy Injections vs Oral GLP-1 Tablets
- SURMOUNT-5: The Head-to-Head Trial of Tirzepatide vs Semaglutide
- Saxenda (Liraglutide) vs Newer GLP-1 Medications